Safety of G-CSF Treatment in Acute Stroke Patients
Author Information
Author(s): Boy Sandra, Sauerbruch Sophie, Kraemer Mathias, Schormann Thorsten, Schlachetzki Felix, Schuierer Gerhard, Luerding Ralph, Hennemann Burkhard, Orso Evelyn, Dabringhaus Andreas, Winkler Jürgen, Bogdahn Ulrich
Primary Institution: Department of Neurology, University of Regensburg, Bezirksklinikum Regensburg, Regensburg, Germany
Hypothesis
Can G-CSF treatment safely mobilize CD34+ stem cells in patients with acute ischemic stroke?
Conclusion
The study demonstrates a good safety profile for G-CSF treatment in acute stroke patients, with some positive functional effects observed.
Supporting Evidence
- G-CSF treatment was started within 12 hours of stroke onset.
- Mobilization of CD34+ cells was observed without significant adverse effects.
- Neuropsychological tests showed improvements in some cognitive functions.
Takeaway
This study tested a medicine called G-CSF to see if it could help people who had a stroke. It was found to be safe and might help some people feel better.
Methodology
Patients were treated with G-CSF in a dose-escalation design and monitored for safety and changes in CD34+ cell counts.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study had a small sample size and was open-label, which may affect the generalizability of the results.
Participant Demographics
20 patients, mean age 55 years, 13 male and 7 female.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website